[Table/Fig-7]:
Clinical success rates among the treatment groups.
| Sub group | Success rate {no. of successes/total no. (%)} for: | ||
|---|---|---|---|
| AAE + Colistin group |
Meropenem + Colistin group | ||
| AAE + Colistin | Meropenem + Colistin |
Shifted to AAE + Colistin |
|
| Evaluable patients for efficacy analysis | 52 | 63 | |
| Overall clinical success | 45/52 (86.53) | 40/63 (63.49) | |
| Treatment regime-wise | - | 40/63(63.49) | 14/23 (60.86) |
| Health Care Associated Pneumonia (HCAP) | 14/16 (87.50) | 14/21 (66.66) | 05/07 (71.42) |
| Hospital Associated Pneumonia (HAP) | 19/21 (90.47) | 15/25 (60.00) | 06/10 (60.00) |
| Bloodstream infections (BSIs) | 09/11 (81.81) | 09/13 (69.23) | 02/04 (50.00) |
| Ventilator Associated Pneumonia (VAP) | 03/04 (75.00) | 02/04 (50.00) | 01/02 (50.00) |
| APACHE II score | |||
| <15 | 15/16 (93.75) | 17/24 (70.83) | 04/07 (57.14) |
| ≥15 | 30/36 (83.33) | 23/39 (58.97) | 10/16 (62.50) |
| Co-morbidities | |||
| Coronary artery disease (CAD) | 9/12 (75.00 %) | 4/10 (40.00 %) | 04/06 (66.66 %) |
| Chronic obstructive pulmonary disease (COPD) | 26/30 (86.66 %) | 19/34 (55.82 %) | 13/15 (86.66 %) |
| Chronic kidney disease (CKD) | 09/13 (69.23 %) | 08/17 (47.05 %) | 06/09 (66.66 %) |
| Diabetes mellitus | 18/23 (78.26 %) | 14/26 (53.84 %) | 10/12 (83.33 %) |
| Cerebrovascular disease | 06/08 (75.00 %) | 05/12 (41.66 %) | 04/07 (57.14 %) |
| Hypertension | 10/14 (71.42 %) | 05/11 (45.45 %) | 05/06 (83.33 %) |